Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468632 | 1.00 | CETP (0.85) | CETP | |
| SCHEMBL993456 | 1.00 | CETP (0.85) | CETP | |
| SCHEMBL6181329 | 0.94 | CETP (0.74) | CETP | |
| SCHEMBL6181331 | 0.94 | CETP (0.74) | CETP | |
| SCHEMBL994609 | 0.93 | CETP (0.73) | CETP | |
| SCHEMBL6182867 | 0.93 | CETP (0.73) | CETP | |
| SCHEMBL6182868 | 0.93 | CETP (0.73) | CETP | |
| SCHEMBL2262660 | 0.93 | CETP (0.73) | CETP | |
| SCHEMBL1565566 | 0.93 | CETP (0.73) | CETP | |
| SCHEMBL992623 | 0.92 | CETP (1.00) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275091-A1 | Pharmaceutical compositions comprising adsorbates of an amorphous drug | Pfizer Products Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| EP-1404302-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ADSORBATES OF AMORPHOUS DRUG | PFIZER PROD INC (US) | 2010-11-03 | — | — | EP | claimed |
| US-20070148236-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | PFIZER PRODUCTS INC. | 2007-06-28 | — | — | US | claimed |
| WO-2006085217-A2 | SOLID ADSORBATES OF HYDROPHOBIC DRUGS | PFIZER PRODUCTS INC. (US) | 2006-08-17 | — | — | WO | claimed |
| EP-1453544-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| EP-1404300-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| EP-1404302-A1 | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AMORPHOUS DRUG | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| EP-1401503-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | claimed |
| EP-1401399-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER AND DRUG ASSEMBLIES | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | claimed |
| EP-1399190-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | Pfizer Products Inc. (US) | 2004-03-24 | — | — | EP | claimed |
| US-20030170309-A1 | Pharmaceutical compositions containing polymer and drug assemblies | BABCOCK WALTER C (US) | 2003-09-11 | — | — | US | claimed |
| US-6586448-B1 | Cholesteryl ester transfer protein inhibitors used as antilipemic agents for prophylaxis of cardiovascular disorders | PFIZER INC. | 2003-07-01 | — | — | US | claimed |
| US-20030104063-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | LONZA BEND INC. | 2003-06-05 | — | — | US | claimed |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER INC. | 2003-01-30 | — | — | US | claimed |
| WO-2003000226-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER AND DRUG ASSEMBLIES | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2003000235-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2003000292-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2003000294-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2003000295-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2003000238-A1 | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AMORPHOUS DRUG | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170309-A1 | Pharmaceutical compositions containing polymer and drug assemblies | PRNP, PUF60, ABCB1 | CETP 315/4885 |
| US-20030104063-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | ABCG2, ABCB1, MATR3 | CETP 534/4885 |
| US-20070148236-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | ABCG2, ALB, SLCO1A2 | CETP 162/4885 |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | CETP, LCAT, LIPA | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.